News Release

Association of injection or IV administration of monoclonal antibodies with COVID-19 outcomes

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

What The Study Did: Researchers evaluated whether receiving by injection the monoclonal antibodies casirivimab and imdevimab was associated with reduced hospitalization and death compared with nontreatment among patients with COVID-19 and whether outcomes were similar if administered by injection or intravenously. Administration by injection could expand outpatient treatment capacity but its effectiveness is unknown.

Authors: Erin K. McCreary, Pharm.D., of the University of Pittsburgh School of Medicine, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.